Trial ID 20138 | Maryland Oncology Hematology Trial ID 20138 – Maryland Oncology Hematology

Trial ID 20138

Trial Information - Phase III

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Protocol ID: D361BC00001

Sponsor: AstraZeneca plc

Status: STAR Trial

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Prostate

Status

STAR Trial

Sponsor

AstraZeneca plc

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology